Establishment of a drug screening model for cardiac complications of acute renal failure

Abstract

Acute renal failure (ARF) is a clinical critical syndrome with rapid and severe decline of renal function. Complications of ARF, especially its cardiac complications (cardiorenal syndrome type 3, CRS‐3), are the main causes of death in patients with ARF. However, the shortage and limited efficacy of therapeutic drugs make it significant to establish new large‐scale drug screening models. Based on the Nitroreductase/Metronidazole (NTR/MTZ) cell ablation system, we constructed a Tg(cdh17:Dendra2‐NTR) transgenic zebrafish line, which can specifically ablate renal tubular epithelial cells. The absence of renal tubular epithelial cells can lead to ARF in zebrafish larvae. The ARF symptoms, such as heart enlargement, slow heart rate and blood stasis, are similar to the clinical manifestations of human CRS‐3. Furthermore, two therapeutic drugs (digoxin and enalapril) com-monly used in the clinical treatment of heart failure were also effective in alleviating the symptoms of CRS‐3 in zebrafish, which proved the effectiveness of this model. Drug screening further discov-ered a potential drug candidate, α‐lipoic acid, which can effectively alleviate the symptoms of CRS‐ 3 through its antioxidant function. Accordingly, we established a new ARF model of zebrafish, which laid a foundation for large‐scale screening of new therapeutic drugs for its complications.